The trial was evaluating HyBryte in a rare form of cancer with limited treatment options. ・The company also plans to assess ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial Diffuse large B-cell ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

Dealing with incurable cancer (I have follicular lymphoma, a form of blood cancer that is considered very treatable, but ...

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B ...

The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment ...

OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

After researching lymphomas for more than a decade and beating the illness herself, NYU Langone professor and alum Lisa Roth ...

Twins pitcher Kody Funderburk and his wife, Alicia, found out they were expecting in September of last year. They welcomed a ...